Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase

Abstract

The development of a quantitative understanding of viral evolution and the fitness landscape in HIV-1 drug resistance is a formidable challenge given the large number of available drugs and drug resistance mutations. We analyzed a dataset measuring the in vitro fitness of 70,081 virus samples isolated from HIV-1 subtype B infected individuals undergoing routine drug resistance testing. We assayed virus samples for in vitro replicative capacity in the absence of drugs as well as in the presence of 15 individual drugs. We employed a generalized kernel ridge regression to estimate main fitness effects and epistatic interactions of 1,859 single amino acid variants found within the HIV-1 protease and reverse transcriptase sequences. Models including epistatic interactions predict an average of 54.8% of the variance in replicative capacity across the 16 different environments and substantially outperform models based on main fitness effects only. We find that the fitness landscape of HIV-1 protease and reverse transcriptase is characterized by strong epistasis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Analysis of predictive power.
Figure 2: Analysis of predictive power of different epistatic models for four representative environments.
Figure 3: Cumulative strength (CS) of the absolute epistatic effects in the HIV-1 protease as measured in the drug-free environment.

References

  1. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 33, 307–320 (2009).

    Article  CAS  Google Scholar 

  2. Shafer, R.W. & Schapiro, J.M. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10, 67–84 (2008).

    PubMed  PubMed Central  Google Scholar 

  3. Clavel, F. & Hance, A.J. HIV drug resistance. N. Engl. J. Med. 350, 1023–1035 (2004).

    Article  CAS  Google Scholar 

  4. Johnson, V.A. et al. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 16, 138–145 (2008).

    PubMed  Google Scholar 

  5. Bennett, D.E. et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4, e4724 (2009).

    Article  Google Scholar 

  6. Petropoulos, C.J. et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44, 920–928 (2000).

    Article  CAS  Google Scholar 

  7. Rhee, S.-Y., Liu, T., Ravela, J., Gonzales, M.J. & Shafer, R.W. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob. Agents Chemother. 48, 3122–3126 (2004).

    Article  CAS  Google Scholar 

  8. Harrigan, P.R. & Larder, B.A. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimicrob. Agents Chemother. 46, 909–912 (2002).

    Article  CAS  Google Scholar 

  9. Croteau, G. et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71, 1089–1096 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Martinez-Picado, J., Savara, A.V., Sutton, L. & D'Aquila, R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73, 3744–3752 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Mammano, F., Trouplin, V., Zennou, V. & Clavel, F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74, 8524–8531 (2000).

    Article  CAS  Google Scholar 

  12. Bonhoeffer, S., Chappey, C., Parkin, N.T., Whitcomb, J.M. & Petropoulos, C.J. Evidence for positive epistasis in HIV-1. Science 306, 1547–1550 (2004).

    Article  CAS  Google Scholar 

  13. Efron, B., Hastie, T., Johnstone, I. & Tibshirani, R. Least angle regression. Ann. Stat. 32, 407–499 (2002).

    Google Scholar 

  14. Candes, E. & Tao, T. The Dantzig selector: statistical estimation when p is much larger than n. Ann. Stat. 35, 2313–2351 (2007).

    Article  Google Scholar 

  15. Nelder, J. & Wederburn, R. Generalized linear models. J. Roy. Stat. Soc. A 135, 370–384 (1972).

    Article  Google Scholar 

  16. Shafer, R.W. Rationale and uses of a public HIV drug-resistance database. J. Infect. Dis. 194 Suppl 1, S51–S58 (2006).

    Article  Google Scholar 

  17. Bershtein, S., Segal, M., Bekerman, R., Tokuriki, N. & Tawfik, D. Robustness–epistasis link shapes the fitness landscape of a randomly drifting protein. Nature 444, 929–932 (2006).

    Article  CAS  Google Scholar 

  18. Halabi, N., Rivoire, O., Leibler, S. & Ranganathan, R. Protein sectors: evolutionary units of three-dimensional structure. Cell 138, 774–786 (2009).

    Article  CAS  Google Scholar 

  19. Hornak, V., Okur, A., Rizzo, R. & Simmerling, C. HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. Proc. Natl. Acad. Sci. USA 103, 915–920 (2006).

    Article  CAS  Google Scholar 

  20. Sanjuán, R., Moya, A. & Elena, S.F. The contribution of epistasis to the architecture of fitness in an RNA virus. Proc. Natl. Acad. Sci. USA 101, 15376–15379 (2004).

    Article  Google Scholar 

  21. Chen, L., Perlina, A. & Lee, C.J. Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. J. Virol. 78, 3722–3732 (2004).

    Article  CAS  Google Scholar 

  22. Provine, W. The Origins of Theoretical Population Genetics (The University of Chicago Press, Chicago, Illinois, USA, 1971).

  23. Wolf, J., Brodie, E. III & Wade, M. Epistasis and the Evolutionary Process (The University of Chicago Press, Chicago, Illinois, USA, 2000).

  24. Costanzo, M. et al. The genetic landscape of a cell. Science 327, 425–431 (2010).

    Article  CAS  Google Scholar 

  25. Yeh, P.J., Hegreness, M.J., Aiden, A.P. & Kishony, R. Drug interactions and the evolution of antibiotic resistance. Nat. Rev. Microbiol. 7, 460–466 (2009).

    Article  CAS  Google Scholar 

  26. Jasnos, L. & Korona, R. Epistatic buffering of fitness loss in yeast double deletion strains. Nat. Genet. 39, 550–554 (2007).

    Article  CAS  Google Scholar 

  27. Kouyos, R.D., Silander, O.K. & Bonhoeffer, S. Epistasis between deleterious mutations and the evolution of recombination. Trends Ecol. Evol. 22, 308–315 (2007).

    Article  Google Scholar 

  28. de Visser, J.A.G.M. & Elena, S.F. The evolution of sex: empirical insights into the roles of epistasis and drift. Nat. Rev. Genet. 8, 139–149 (2007).

    Article  CAS  Google Scholar 

  29. Petropoulos, C.J. Data management plan for Monogram BioSciences. Nature Precedings <http://dx.doi.org/10.1038/npre.2011.5668.1> (2011).

  30. Dykes, C. & Demeter, L.M. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin. Microbiol. Rev. 20, 550–578 (2007).

    Article  CAS  Google Scholar 

  31. Rhee, S.-Y. et al. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. USA 103, 17355–17360 (2006).

    Article  CAS  Google Scholar 

  32. Martins, J.Z. et al. Principal component analysis of general patterns of HIV-1 replicative fitness in different drug environments. Epidemics 2, 85–91 (2010).

    Article  Google Scholar 

Download references

Acknowledgements

T.H., J.M. and S.B. thank the Swiss National Science Foundation (NF 3100A0-116408) for financial support. We thank R. Regös, R. Kouyos, J. Engelstädter, S. Alizon and T. Gernhard-Stadler for valuable comments and critical reading of the manuscript.

Author information

Authors and Affiliations

Authors

Contributions

T.H. developed and implemented the generalized kernel ridge regression and analyzed data. J.M. analyzed data. C.C., M.H., E.S., J.M.W. and C.J.P. generated and pre-processed the experimental data. S.B. designed the study and analyzed data. T.H. and S.B. wrote the paper.

Corresponding authors

Correspondence to Christos J Petropoulos or Sebastian Bonhoeffer.

Ethics declarations

Competing interests

C.C., M.H., E.S., J.M.W. and C.J.P. are or have been employees of Monogram BioSciences and are named inventors on US and foreign patents held by Monogram BioSciences. S.B. is a consultant of Monogram BioSciences.

Supplementary information

Supplementary Text and Figures

Supplementary Note and Supplementary Figures 1–3. (PDF 1876 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hinkley, T., Martins, J., Chappey, C. et al. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet 43, 487–489 (2011). https://doi.org/10.1038/ng.795

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.795

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing